Tim O'Reilly
2008/07/08
|
I read recently about the cease and desist letters sent to 23andme and other personal genomics companies selling tests directly to consumers. 23andme has responded, saying that they agree with the ultimate need for regulation, but that harnessing the consumer internet for personal genomics is a really valuable scientific tool.
I have to say I find myself doubtful about the urgency of this regulatory move. It smacks more of the hand of the AMA, an entrenched industry trying to make sure that the new tools of genetic testing remain under the thumb of doctors, than of true consumer protection. You have only to walk into Whole Foods to encounter a multi-billion dollar industry of supplements making all kinds of dubious health claims, which is completely unregulated. Why pick on personalized medicine, which has way more substance, and at least so far, way more care in the types of claims it makes? I'm a happy 23andme customer, and it's hard for me to see how the information they provide consists in any way of medical advice that should be subject to regulation. They are very clear to mark the scientific status of any genetic studies they report on, and never begin to presume to diagnostics. In many ways, the service is a kind of "RSS for the genome," feeding you the results of the latest scientific studies that might be relevant to you. You can find these same studies simply by googling for them. 23andme simply says "this might be relevant" using data that you've provided about yourself via your genetic sample. The benefits of what companies like 23andme are doing is enormous. Once you understand even a tiny bit about how genes affect our response to drugs, you realize just how flawed many clinical studies are. If people have different genetically programmed response to drugs, what is the right dosage? Is the drug effective? (What if it's 100% effective for 3% of the population, due to their genetics, while it's completely ineffective for the rest. Would we ever know?) Ideally, every clinical study going forward would have a genetic screening component. And new studies should be done on old treatments to correlate their effectiveness with genetic data. But that's hugely expensive. 23andme (and presumably other similar services) have come up with a very clever hack that will vastly increase the available store of genetic information that can be used to cross check various medical studies. They recruit a large population of those who are merely curious. But once that genotype data is available, they can begin to do surveys of their user population to gather corresponding phenotype data. (That is, matching genetic data with observable characteristics.) This will be a boon to science. As Linda Avey, one of the founders, wrote on the 23andme blog: Our first mission is to enable personal access to genetic information and provide a look, through the prism of an individual’s genome, at the flood of research discoveries being published. Our longer-term goal is to utilize a web-based platform that gives individuals the ability to share details related to their personal traits-including diseases they have and how they respond to therapies-uniformly layered on their genetic profiles to start building the evidence needed to drive targeted diagnoses and treatments. I hope that regulators will seize the opportunity provided by the consumer internet to open up the frontier of personalized medicine. This is our data, the most personal data we have. I don't see why it should be forced into the straight-jacket of the 20th century medical industry. We tried that with music, and what did that get us?
I'd say to let this area run for a while, and start thinking about regulation if and when it starts to go awry. Right now, the companies I'm aware of are being very careful not to promise anything that needs to be regulated.
|
翻译:yuwen
最近我读到关于向23andme以及其他公司发出停止信的报道,这封信是发给23andme以及其他向消费者直接销售基因测试的个人基因公司。23andme已经做出回应,他们同意管理的必要性,但也强调通过互联网对于个人基因组是非常有价值的科研工具。 我不得不怀疑现在做这样的管制的必要性。我闻到些许AMA的味道,这个产业希望基因测试的新工具仍旧能够被医生所控制,而不是真要保护消费者。你只要走进Whole Foods就会有所体会,这样数十亿美元的产业做着各种没谱的健康声明,他们才需要彻底的管制。为什么对个性化医疗这样苛刻? 我是一个很满意的23andme客户,而且我看不到他们提供的信息有什么需要管制的内容。他们非常明确地给出了基因研究的科研状态,从没有任何诊断。很大程度上这一服务是一种“基因组RSS”,告诉你可能与你有关的最新科研成果。你只要简单地搜一下就可以找到同样的研究信息。23andme使用你通过基因样本提供的数据仅仅是说“这可能有关联”。 23andme这些公司做的事情意义非凡。一旦你理解了(哪怕是一点点)基因如何影响药物对你的作用,你就会认识到很多临床研究有多差劲。如果人们根据基因情况对药物有不同的反应,那什么是药物的正确剂量?这个药有效吗?(如果一个药由于基因的原因对3%的人100%有效,而对其他人毫无效果,怎么办?) 理想情况下每一个临床研究都应该有基因筛查环节。而且过去的治疗方法也应该结合基因数据作新的研究。但这将非常昂贵。 23andme(以及其他类似服务)的出现提供了一个聪明的办法,将极大提高可用基因信息,可以用来与各种医疗研究作比对。他们只是动员了大量有好奇心的人来参加。一旦基因型数据可用就可以着手调查用户群来搜集相应的显型数据。(也就是来匹配基因数据和临床观测症状。) 这将是科学带给我们的恩赐。正如创始人之一Linda Avey在23andme博客中写道:
我希望管理部门能抓住互联网提供的机遇,开放个性化医疗的前沿阵地。这是我们的数据,我们自己拥有的最私人的数据。我看不到为什么一定要将这些禁锢在上个世纪的医疗体系之中。在音乐领域我们曾那样做过,又得到了什么? 我想说让这一领域再发展一个阶段,如果真有问题再开始考虑必要的管制。现在我所知道的公司对于那些需要管制的内容都非常谨慎。 |
Discussion
支持个性化医疗。任何资源以及新的、先进的科学技术武器再也不能被产业寡头霸占,比如石油……